Differences in pharmacology of tumor necrosis factor (TNF) antagonists
The commercially available inhibitors of TNF are constituted by two classes of molecules: the soluble receptors (Etanercept: Amgen Inc. Wyeth) and the monoclonal antibodies (Adalimumab: Abbott Laboratories and Infliximab: Centocor, Inc.). The differences in their molecular structure, mechanism of ac...
Saved in:
Main Authors: | S. Bombardieri (Author), U. Fiocco (Author) |
---|---|
Format: | Book |
Published: |
PAGEPress Publications,
2011-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease
by: Cristián Navarrete-Dechent, et al.
Published: (2015) -
Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking
by: Liang Liang Bai, et al.
Published: (2021) -
Intra-articular therapy with tumor necrosis factor-α antagonists: an update
by: S. Bello, et al.
Published: (2014) -
High Level of Tumor Necrosis Factor (TNF)-α is a Risk Factor for Preeclampsia
by: I.G.N. Anom
Published: (2012) -
Treatment patterns of snti-TNF agents in Italy: an observational study
by: C. Ferri, et al.
Published: (2011)